This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 3 of 38 for:    salpingectomy

Impact of Salpingectomy on Ovarian Reserve (SALPOVA)

This study is currently recruiting participants.
See Contacts and Locations
Verified October 2016 by Hospices Civils de Lyon
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT02284711
First received: November 4, 2014
Last updated: October 31, 2016
Last verified: October 2016
  Purpose

Epithelial cancer of the ovaries is the most severe form of gynecologic cancer; a significant proportion of ovarian cancers originate from the Fallopian tube. Guidelines therefore now recommend systematically associating prophylactic salpingectomy to benign hysterectomy. The principal objective of the present study is to assess the impact of salpingectomy on ovarian reserve by anti-Müllerian hormone (AMH) assay and calculating the Doppler index of vascular resistance in the ovarian vessels. The secondary objective is to compare ovarian reserve results between two coagulation techniques used in salpingectomy: bipolar electric energy versus ultrasound.

The study design is single-center, prospective, before-and-after, with open randomization between two groups defined by coagulation technique.


Condition Intervention
Laparoscopic Salpingectomy Device: Bipolar electric energy Device: ultrasound energy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Impact of Salpingectomy on Ovarian Reserve, With Comparison Between Two Coagulation Techniques

Resource links provided by NLM:


Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • AMH level [ Time Frame: 3 months post-surgery ]

Secondary Outcome Measures:
  • AMH level [ Time Frame: 1 month post-surgery ]
  • index of vascular resistance in the ovarian vessels [ Time Frame: 1 and 3 months post-surgery ]
  • menopausal quality of life score [ Time Frame: 1 and 3 months post-surgery ]

Estimated Enrollment: 80
Study Start Date: March 2015
Estimated Study Completion Date: September 2020
Estimated Primary Completion Date: September 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Bipolar
Coagulation during salpingectomy using conventional bipolar electric energy
Device: Bipolar electric energy
Coagulation during salpingectomy using conventional bipolar electric energy
Active Comparator: Ultrasound
Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
Device: ultrasound energy
Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female subjects aged 18
  • Scheduled surgery: bilateral laparoscopic salpingectomy associated to hysterectomy for benign indication

Exclusion Criteria:

  • Interview revealing disorder entailing unacceptable risk of postoperative complications: coagulation disorder, immune system disorder, evolutive disease, etc.
  • Pregnancy, ongoing or planned during the study period
  • History of bilateral salpingectomy
  • Salpingectomy associated with pelvic cancer
  • Oral hormonal contraception during the study period
  • Menopause
  • Inability to understand information provided
  • Not covered by a national health insurance scheme, prisoner or under administrative supervision.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02284711

Contacts
Contact: Gery LAMBLIN, Dr 4 72 35 58 71 ext +33 gery.lamblin@chu-lyon.fr

Locations
France
Hospices Civils de Lyon - HFME Recruiting
Lyon, France, 69003
Contact: Gery LAMBLIN         
Sponsors and Collaborators
Hospices Civils de Lyon
  More Information

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT02284711     History of Changes
Other Study ID Numbers: 69HCL14_0166
Study First Received: November 4, 2014
Last Updated: October 31, 2016

Keywords provided by Hospices Civils de Lyon:
salpingectomy, ovarian reserve, coagulation technique

ClinicalTrials.gov processed this record on September 21, 2017